KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly

KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly

Item
http://www.wikidata.org/entity/Q21564039
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trialsNo association of VAMP8 gene polymorphisms with glioma in a Chinese Han populationNo evidence for cardiac dysfunction in Kif6 mutant miceMeta-analyses of KIF6 Trp719Arg in coronary heart disease and statin therapeutic effect.Expression, regulation and putative nutrient-sensing function of taste GPCRs in the heart.Novel KIF6 polymorphism increases susceptibility to type 2 diabetes mellitus and coronary heart disease in Han Chinese menABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatmentSeventeen years of statin pharmacogenetics: a systematic review.Extraoral bitter taste receptors in health and disease.The Trp719Arg polymorphism of the KIF6 gene and coronary heart disease risk: systematic review and meta-analysis.Association between taste receptor (TAS) genes and the perception of wine characteristics.Variability in Human Bitter Taste Sensitivity to Chemically Diverse Compounds Can Be Accounted for by Differential TAS2R Activation.Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and KIF6 and HMG-CoA Genotypes in a Subset of the Brisighella Heart Study Population.Association between KIF6 rs20455 polymorphism and the risk of coronary heart disease (CHD): a pooled analysis of 50 individual studies including 40,059 cases and 64,032 controls.
P2860

KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly

Item
http://www.wikidata.org/entity/Q21564039
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
KIF6, LPA, TAS2R50, and VAMP8 ...... risk reduction in the elderly
@ast
KIF6, LPA, TAS2R50, and VAMP8 ...... risk reduction in the elderly
@en
KIF6, LPA, TAS2R50, and VAMP8 ...... risk reduction in the elderly
@en-gb
KIF6, LPA, TAS2R50, and VAMP8 ...... risk reduction in the elderly
@nl
type
label
KIF6, LPA, TAS2R50, and VAMP8 ...... risk reduction in the elderly
@ast
KIF6, LPA, TAS2R50, and VAMP8 ...... risk reduction in the elderly
@en
KIF6, LPA, TAS2R50, and VAMP8 ...... risk reduction in the elderly
@en-gb
KIF6, LPA, TAS2R50, and VAMP8 ...... risk reduction in the elderly
@nl
prefLabel
KIF6, LPA, TAS2R50, and VAMP8 ...... risk reduction in the elderly
@ast
KIF6, LPA, TAS2R50, and VAMP8 ...... risk reduction in the elderly
@en
KIF6, LPA, TAS2R50, and VAMP8 ...... risk reduction in the elderly
@en-gb
KIF6, LPA, TAS2R50, and VAMP8 ...... risk reduction in the elderly
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
KIF6, LPA, TAS2R50, and VAMP8 ...... risk reduction in the elderly
@en
P2093
P304
P31
P356
10.1016/J.ATHEROSCLEROSIS.2011.11.037
P407
P433
P478
P50
P577
P698
P921